account_balance
Investment manager · 13F filer · SEC CIK 1831942
Commodore Capital LP
Reported value$1.68Bas of Jun 30, 2026
Positions33 5 new, 8 sold out
Top 10 weight68.2%RLAY alone is 13%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
RLAYRelay Therapeutics Inc
13.4%Trimmed −29%
ELVNEnliven Therapeutics Inc
9.9%
ALKSAlkermes PLC
9.4%Trimmed −29%
COGTCogent Biosciences Inc
7.0%Added +6%
AMLXAmylyx Pharmaceuticals Inc
6.0%
DFTXDefinium Therapeutics Inc
5.6%
SYRESpyre Therapeutics Inc
4.5%Trimmed −56%
ANROAlto Neuroscience Inc
4.3%
TNGXTango Therapeutics Inc
4.2%New
EYPTEyepoint Inc
3.9%Added +63%
TYRATyra Biosciences Inc
3.6%Trimmed −24%
DMRADamora Therapeutics Inc
3.0%
RLAYRelay Therapeutics Inc
13.4%Trimmed −29%
ELVNEnliven Therapeutics Inc
9.9%
ALKS9.4%COGT7.0%AMLX6.0%DFTX5.6%SYRE4.5%ANRO4.3%TNGX4.2%EYPT3.9%TYRA3.6%DMRA3.0%Boxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
RLAY Relay Therapeutics Inc 13.4% Trimmed −29%ELVN Enliven Therapeutics Inc 9.9% HeldALKS Alkermes PLC 9.4% Trimmed −29%COGT Cogent Biosciences Inc 7.0% Added +6%AMLX Amylyx Pharmaceuticals Inc 6.0% HeldDFTX Definium Therapeutics Inc 5.6% HeldSYRE Spyre Therapeutics Inc 4.5% Trimmed −56%ANRO Alto Neuroscience Inc 4.3% HeldTNGX Tango Therapeutics Inc 4.2% NewEYPT Eyepoint Inc 3.9% Added +63%TYRA Tyra Biosciences Inc 3.6% Trimmed −24%DMRA Damora Therapeutics Inc 3.0% Held
What changed